The price of Adalimumab Adaz varies depending on factors such as dosage, quantity, and pharmacy. For instance, a 100 mg/0.8 mL prefilled pen of Adalimumab Adaz is listed at approximately $5,130.09 [1]. A 40 mg/0.4 mL prefilled syringe can cost around $2,564.93 [1].
How to Find the Best Price for Adalimumab Adaz
Patients seeking to manage the cost of Adalimumab Adaz can explore several options. Many pharmacies offer discount cards or coupons that can reduce out-of-pocket expenses [2]. Additionally, patient assistance programs, often run by manufacturers or independent organizations, may provide financial aid for eligible individuals [2]. Comparing prices across different pharmacies, both online and brick-and-mortar, can also lead to significant savings [2].
What is Adalimumab Adaz Used For?
Adalimumab Adaz is a biosimilar to adalimumab, a medication used to treat a variety of autoimmune conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and uveitis [3]. It works by blocking a protein in the body that causes inflammation [3].
When Does Adalimumab Adaz Patent Expiry?
As a biosimilar, Adalimumab Adaz is approved for use after the patents on the reference product, adalimumab (Humira), have expired or are nearing expiry in certain regions. Patent protection for originator drugs like Humira is complex and can involve multiple patents covering different aspects of the drug, such as formulation, method of use, and manufacturing processes [4]. Information regarding specific patent expiry dates for Humira and the subsequent market entry of biosimilars like Adalimumab Adaz can be found on resources like DrugPatentWatch.com [4].
Who Makes Adalimumab Adaz?
Adalimumab Adaz is manufactured by Samsung Bioepis [3]. Samsung Bioepis is a biopharmaceutical company that develops and commercializes biosimilars and innovative biologics [3].
How Does Adalimumab Adaz Compare to Humira?
Adalimumab Adaz is a biosimilar to adalimumab, the active ingredient in Humira. Biosimilars are highly similar to their reference products and have no clinically meaningful differences in terms of safety, purity, and potency [3]. This means Adalimumab Adaz is expected to have the same therapeutic effect as Humira for the same indications [3]. The availability of biosimilars like Adalimumab Adaz can lead to increased competition and potentially lower prices for patients [5].
What Side Effects Are Associated with Adalimumab Adaz?
Like other TNF blockers, Adalimumab Adaz can cause serious side effects. These include infections, an increased risk of certain cancers, and allergic reactions [3]. Common side effects may involve injection site reactions, upper respiratory infections, headache, rash, and nausea [3]. Patients should discuss potential risks and benefits with their healthcare provider.
---
Sources:
[1] https://www.goodrx.com/adalimumab-adaz
[2] https://www.adalimumab-adaz.com/savings-and-support/
[3] https://www.adalimumab-adaz.com/
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/patients/learn-about-biologics-and-biosimilars/what-biosimilars-are